Sirolimus-eluting coronary stent - Carbostent and Implantable Devices

Drug Profile

Sirolimus-eluting coronary stent - Carbostent and Implantable Devices

Alternative Names: Cre8; DES - Cre8™

Latest Information Update: 02 Jun 2015

Price : $50

At a glance

  • Originator Carbostent & Implantable Devices
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2014 Phase-III clinical trials in Coronary artery disease in China (Intracoronary)
  • 16 Jul 2011 Registered for Coronary artery disease in European Union (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top